Skip to main content

Search This Blog

Pulmonary Hypertension

Posts

HFpEF: Heart Failure with Preserved Ejection Fraction

Get link
Facebook
X
Pinterest
Email
Other Apps

October 13, 2026

Invalid Access Key! Invalid Access Key!

Group 3 Pulmonary Hypertension: From Bench to Bedside

Get link
Facebook
X
Pinterest
Email
Other Apps

October 13, 2026

Invalid Access Key! Invalid Access Key!

Abstract - 2026 - Pediatric Pulmonology

Get link
Facebook
X
Pinterest
Email
Other Apps

October 13, 2026

Invalid Access Key! Invalid Access Key!

A Review of the Mechanism of Action of Drugs Used in Congestive Heart Failure in Pediatrics

Get link
Facebook
X
Pinterest
Email
Other Apps

October 12, 2026

Invalid Access Key! Invalid Access Key!

Pulmonary Vascular Dysfunctions in Cystic Fibrosis

Get link
Facebook
X
Pinterest
Email
Other Apps

October 12, 2026

Invalid Access Key! Invalid Access Key!

Abstract - 2026 - Pediatric Pulmonology

Get link
Facebook
X
Pinterest
Email
Other Apps

October 12, 2026

Invalid Access Key! Invalid Access Key! Explore the things you love . ...

Powered by Blogger

Theme images by 4x6

Archive

October14
September59
August59
July47
June22
May41
April32
March70
February59
January81

Show more Show less

Popular posts from this blog

Aria Raises $31M for Planned Study of Balloon Implant to Treat PAH - Pulmonary Hypertension News

Aria Raises $31M for Planned Study of Balloon Implant to Treat PAH - Pulmonary Hypertension News Aria Raises $31M for Planned Study of Balloon Implant to Treat PAH - Pulmonary Hypertension News Posted: 02 Mar 2020 12:00 AM PST Aria CV announced the end of a funding round that will be used to finance a feasibility study of its medical device, the Pulmonary Hypertension System (Aria CV PH System), in people with pulmonary arterial hypertension (PAH) in the U.S. The series B round, which raised $31 million, was led by Xeraya Capital . "Aria CV is now well positioned to drive our clinical research forward," Dan Gladney, the company's chief executive officer and president, said in a press release . "We are grateful for this validation by our investors and remain committed to bringing this innovative treatment option to PAH patients," Gladney added. Pulmonary hyperte...

Afib: Causes, Symptoms, and Treatment Options

medical pah :: Article Creator As PAH Science Advances, Trial Design Comes Under Microscope Investigators are considering how best to interpret the results of potential new therapies. The science of pulmonary arterial hypertension (PAH) has advanced significantly in recent years. However, as the push for new and better therapies gains momentum, clinical trial investigators are thinking long and hard about how best to demonstrate and interpret patient improvement. One issue has to do with the question of which end points are best to meaningfully track patient responses to therapies. Marius Hoeper, MD, of Germany's Hannover Medical School, said in clinical practice, physicians tend to use a variety of measures to track patient improvement. "PH physicians usually take a holistic view," he said, "i.E., they consider the broad picture." That broad picture includes everything from patient's exercise capacity, assessed b...

Evaluation and Management of Pulmonary Hypertension in ...

September 13, 2023

pulmonary fibrosis causes :: Article Creator Glycogen Metabolism May Play A Key Role In Pulmonary Fibrosis Ramon Sun and his team use MALDI-MSI to investigate aberrant metabolism in diseases including pulmonary fibrosis. Cameron Shedlock Most people take breathing for granted, but patients with interstitial lung diseases (ILDs) remember its importance every time they struggle to take a breath. Many patients with ILDs develop pulmonary fibrosis, which is the gradual scarring of the lungs. This progressive and fatal process results from excessive extracellular matrix production and deposition by lung fibroblasts and myofibroblasts, where collagen, elastin, and N-linked glycans are the major components of the matrix.1 Ultimately, pulmonary fibrosis results in the thickening of the alveolar walls, which limits oxygen uptake and causes difficulty breathing. ILDs with pulmonary fibrosis can result from genetic mutations, an underlying disease, o...

Labels

"pulmonary hypertension prognosis" - Google News
idiopathic pulmonary hypertension
IFTTT
mild pulmonary hypertension
pulmonary artery hypertension
Pulmonary Hypertension
pulmonary hypertension causes
pulmonary hypertension diagnosis
pulmonary hypertension medications
pulmonary hypertension prognosis

pulmonary hypertension symptoms
pulmonary hypertension treatment
severe pulmonary hypertension
what is pulmonary hypertension

Show more Show less

yand